I completely agree, BXN is positioned very differently from the typical cannabis companies focused on farming.
Their strength lies in producing high-quality, pharmaceutical-grade products, and the growing gummy demand is a huge opportunity.
On top of the previously announced deals, I think the recent contract extension with Aura Therapeutics is another strong indicator of their momentum. This deal could add $5.94 million in sales annually, with $3.14 million coming from gummies and the rest from THC flower products.
Plus, doubling the forecast volume for THC flower shows the strong demand they’re meeting.It’s great to see BXN securing long-term partnerships like this, which solidifies their role as a key player in both the cannabis and emerging psychedelics markets. With Australia quickly becoming a hub for medicinal cannabis and psychedelics, BXN is leading the charge with their GMP-certified production.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)